loader from loading.io

Elizabeth Nielson and Ingmar Gorman - The Importance of Psychedelic Integration Training for Therapists

Psychedelics Today

Release Date: 02/18/2020

PT 652 - Esme Dark - Psychedelics, Somatics and the Shadow show art PT 652 - Esme Dark - Psychedelics, Somatics and the Shadow

Psychedelics Today

Dr. Esme Dark joins Kyle Buller for a conversation on psychedelic therapy, somatic psychotherapy, and shadow work. Based in Australia, Dark is a clinical psychologist, somatic psychotherapist, and psychedelic therapist. She shares her perspective on Australia’s authorized prescriber model, the role of psychotherapy in psychedelic care, and what it means to work with the body before, during, and after a psychedelic experience. The discussion stays practical. Dark draws on her work in research settings, including psilocybin-assisted psychotherapy for generalized anxiety disorder at Monash...

info_outline
PT 651 - Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research, and the Future of Psychedelics show art PT 651 - Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research, and the Future of Psychedelics

Psychedelics Today

MAPS co-executive directors Betty Aldworth and Ismail Ali join Psychedelics Today to talk about leading one of the most visible organizations in the psychedelic field during a period of transition. The conversation covers their move into permanent leadership, how they work together, and how MAPS is thinking about research, education, policy, and movement strategy after a difficult period for the organization and the broader field.

info_outline
PT 650 - Joe Moore Psychedelics Today on Leadership, Integration, and the Psychedelic Landscape show art PT 650 - Joe Moore Psychedelics Today on Leadership, Integration, and the Psychedelic Landscape

Psychedelics Today

Jen Davenport joins Psychedelics Today to interview co-founder Joe Moore about the growth of Psychedelics Today, the broader psychedelic ecosystem, and how professionals are beginning to engage with psychedelic ideas. Davenport is the founder of Iron Thread Partners and a graduate of the Vital psychedelic training program. Her work focuses on executive leadership, decision making, and organizational development. In this conversation she asks Moore about the evolution of Psychedelics Today and the changes he has witnessed across the psychedelic field over the past decade. Moore explains that...

info_outline
PT 649 - Melissa Lavasani and Jay Kopelman show art PT 649 - Melissa Lavasani and Jay Kopelman

Psychedelics Today

& join our podcast to discuss how psychedelic policy is actually moving in Washington, DC. Lavasani leads , a DC-based advocacy organization focused on educating federal officials and advancing legislation around psychedelic medicine. Kopelman is CEO of , which provides scholarships for veterans and first responders seeking psychedelic-assisted therapy retreats, . The conversation centers on veterans, the , and why that system may be the first realistic federal pathway for psychedelic care. Early Themes Lavasani describes PMC’s work on , including hosting events that bring...

info_outline
PT 648 - Enamory - Couples Therapy with Ketamine show art PT 648 - Enamory - Couples Therapy with Ketamine

Psychedelics Today

Enamory is a clinical practice, training institute, and nonprofit research organization focused on psychedelic assisted couples therapy. In this episode, clinical psychologists Chandra Kian and Kayla Knopp discuss their work integrating ketamine assisted psychotherapy with evidence based couples therapy models. Both guests trained as academic researchers at the University of California San Diego Veterans Affairs system, where they worked on large scale couples based PTSD trials. They later co founded Enamory to continue clinical work, train therapists, and conduct research focused...

info_outline
PT 647 - Joshua White: Fireside Project and Lucy, an AI Training Simulator for Psychedelic Support show art PT 647 - Joshua White: Fireside Project and Lucy, an AI Training Simulator for Psychedelic Support

Psychedelics Today

is a nonprofit that helps reduce the risks of psychedelic experiences through a free support line, coaching, education, and research. In this episode, Joshua White speaks with Psychedelics Today about why real-time support matters, what it takes to run a national hotline, and what Fireside learned after more than 30,000 conversations since launch. White shares how his background as a lawyer and his early hotline volunteering shaped Fireside’s model. He also describes how festival harm reduction work, including lessons from Zendo-style support spaces, revealed a major gap: people often...

info_outline
PT 646 - Manvir Singh: Shamanism the Timeless Religion show art PT 646 - Manvir Singh: Shamanism the Timeless Religion

Psychedelics Today

Manvir Singh joins Psychedelics Today to unpack what shamanism means and why the term matters now. Singh is an anthropologist and author of Shamanism: The Timeless Religion. He argues that shamanism is not limited to “remote” societies or the past. Instead, it reliably reappears because it helps humans manage uncertainty, illness, and the unknown. This episode is relevant for the psychedelic community because “shaman” often gets used loosely, or avoided entirely. Singh offers a clear framework for talking about shamanic practice without leaning on romantic myths, drug-centered...

info_outline
PT 645 - Oli Genn-Bash: Functional Mushrooms, Hype Cycles, and Mycelial Thinking show art PT 645 - Oli Genn-Bash: Functional Mushrooms, Hype Cycles, and Mycelial Thinking

Psychedelics Today

(Brighton, UK) joins Joe Moore for a grounded conversation on the boom in functional mushrooms and why the category may be moving too quickly. As the founder of , Oli works with consumers and brands to demystify functional mushrooms, with a focus on education, traceability, and realistic expectations. The conversation begins with a critique of wellness hype cycles. Oli explains how consumer desperation for help with anxiety, sleep, stress, and cognition can create an opening for a rapid wave of products that are not always grounded in careful sourcing or clear science. Using as a case...

info_outline
PT 644 - Tricia Eastman: Seeding Consciousness, Ancestral Wisdom, and Psychedelic Initiation show art PT 644 - Tricia Eastman: Seeding Consciousness, Ancestral Wisdom, and Psychedelic Initiation

Psychedelics Today

In this live episode, joins to discuss . She explains why many Indigenous initiatory systems begin with consultation and careful assessment of the person, often using divination and lineage-based diagnostic methods before anyone enters ceremony. Eastman contrasts that with modern frameworks that can move fast, rely on short trainings, or treat the medicine as a stand-alone intervention. Early Themes: Ritual, Preparation, and the Loss of Container Eastman describes her background, including ancestral roots in Mexico and her later work at Crossroads Ibogaine in Mexico, where she supported...

info_outline
PT 643 - Logan Davidson - American Ibogaine, State Strategy, and the Future of Psychedelic Policy show art PT 643 - Logan Davidson - American Ibogaine, State Strategy, and the Future of Psychedelic Policy

Psychedelics Today

Logan Davidson joins the show to talk about the fast-moving world of Ibogaine in American and why state-based leadership is shaping the future of psychedelic reform. Davidson is the executive director of , the legislative director at , and a key strategist behind Texas’ landmark interest in ibogaine research. He also advises for . His work sits at the intersection of science, policy, and lived experience, and this conversation offers a clear look into what is happening right now. Early Themes: The Rise of State Advocacy Davidson explains how he entered politics at nineteen and how his...

info_outline
 
More Episodes

In this Episode, Kyle sits down with Elizabeth Nielson and Ingmar Gorman, Co-founders of Fluence, Training in Psychedelic Integration. They are both therapists on the MAPS clinical trial for MDMA Assisted Psychotherapy for PTSD.

3 Key Points:

  1. Elizabeth and Ingmar are co-founders of Fluence, an online Psychedelic Integration Training program.
  2. If psychedelic treatments become available more widely, the fear is that therapists won't be as educated on how to handle their patient interactions based on the behavior of each psychedelic. Psychedelic Integration Therapy Training is so important.
  3. There are 3 phases to the MDMA for PTSD clinical trial. Phase 1 would be pre-clinical data about the chemistry of a drug, Phase 2 is where you begin to test your treatment in a patient population, and Phase 3 is where you get the data to demonstrate that the treatment is superior to a placebo and other treatments in general.

Support the show

Navigating Psychedelics


Show Notes

About Ingmar

  • Ingmar is a previous guest of the show
  • He is a private Investigator for the MAPS MDMA trial
  • He is a therapist and the Co-founder of Fluence

About Elizabeth

  • Elizabeth is a Clinical Psychologist
  • She has a long history in working with clinical trials as a therapist
  • She is part of the psychedelic education and continuing care program
  • She does a lot of supervision and training for therapists

The Trial

  • The approval of expanded access by the FDA includes 50 people in total
  • They are near the end of MAP 1 (out of MAP 1 and MAP 2)
    • When they transition into MAP 2, it will be a little more refined
    • MAP 2 is different participants than MAP 1
  • There are 3 phases
    • Phase 1 would be pre-clinical data about chemistry of a drug and how it metabolises, if its poisonous, etc
    • Phase 2 is where you begin to test your treatment in a patient population
    • Phase 3 is where you get the data to demonstrate that the treatment is superior to a placebo and other treatments in general
    • They are done as a double-blind trial, both the therapist and patient don't know if the patient is receiving the treatment or now

Take-aways

  • There is a lot of information that has to be shared effectively
  • The therapists are very much in the lives of the participants on top of just the MDMA
  • Instead of learning from the trials of what to do on a practical level, its about inspiring them to bring this as an actual treatment for people
  • The multiple ways that PTSD can manifest and look like, and the may ways that MDMA can look like when administered, have some commonalities
    • The deepening, the broadening, the way they communicate, can all be the same
  • Ingmar holds the belief in the inner healing intelligence of all people
    • One of the first things he does when he begins with a new patient, he says that this is something he really believes in, and his role as a therapist to help them in their own healing process and mechanism
  • What Elizabeth wanted to learn, know and practice while she was going through school, isn't what she she thought it was until she found it
    • She says this work really requires them to trust people's minds and experiences
    • There is something that they tell their patients, “Don't get ahead of the medicine” - Elizabeth
  • There is an interesting paradox between not knowing and following intuition, to having an actual method and following that
    • There is a sweet spot between following a script to following your intuition as a therapist
    • You want to trust that inner healer process of the patient, but also need to know when to intervene (usually from a safety standpoint)

Fluence

  • 3 days after Horizons, Elizabeth was at home with a cold, and talked to Ingmar that morning curious for a name for the project
  • Fluence means, magical or mystical power or source of power
    • It can also refer to the density of particles of energy
  • They teach about harm reduction and integration with their patients in their practice
    • They aren't teaching protocols in the workshops, they just think the harm reduction is important
  • The last part of integration is mindfulness
  • Ingmar’s biggest influence are his clients and patients, he is so inspired by them
    • A large piece of the motivation for creating Fluence is from patients just looking for someone to talk about their experience with

The Why

  • A mother whose teenage daughter with depression, reached out to Ingmar with trouble trying to treat her depression
    • The family decided it would be a good idea to use Ketamine therapy, which was successful
    • She was doing so well, so well that she then went to a therapist to integrate it
    • The therapist that she went to then instead of responding positively, decided to fire the teen for further therapy, and report the parents to child care services for providing ketamine therapy
    • Ingmar says their position is not that everyone needs psychedelic integration therapy, its specifically for those that don't feel supported by family or community, and it gives them a professional service as an option
  • "Psychedelics are not 10 years of change in one night, they are 10 years of insight in one night. integration is so important." - Elizabeth
  • The goal is to support people in making a change that feels safe and right for them
  • If the treatments become available more widely, the fear is that therapists won't be as educated on how to handle their patient interactions based on the behavior of each psychedelic
    • Mental health practitioners can be a great source for working through those experiences

Menla Training

  • Menla Training
  • They could really take their time with the process and training
  • The trainings that they had gone to has made their own Fluence courses better
  • In 2019 they had 5 of the trainings for clinicians, and the trainings will be better and better as they go

Ketamine Infusion Therapy

  • The experience is not dose dependent
  • The purpose of the workshop is to educate both therapists and doctors about what can happen in psychotherapy

Links

Fluence

Psychedelics 101 and 102 Workshop at ICPR 2020


About Elizabeth

Dr. Elizabeth Nielson is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, MDMA-assisted treatment PTSD, and psilocybin-assisted treatment of treatment resistant depression. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her program of research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.

About Ingmar

Dr. Ingmar Gorman is a co-founder of Fluence and a psychologist who specializes in assisting populations who have a relationship with psychedelics. He is the site co-principal investigator and therapist on a Phase 3 clinical trial studying MDMA-assisted psychotherapy for post-traumatic stress disorder. Dr. Gorman is a board member of Horizons Media, Inc., a not for-profit educational charity and organizer of the Horizons Conference: Perspectives on Psychedelics. After completing his NIH postdoctoral fellowship at New York University, Dr. Gorman stepped down as director of the Psychedelic Education and Continuing Care Program to focus his efforts on Fluence and the training of future therapists.

Designed to help the body with cellular energy and cardiovascular endurance.

Get a 30 day free audible trial at audibletrial.com/psychedelicstoday